摘要
目的观察莫沙必利联合艾司奥美拉唑肠溶胶囊对老年慢性萎缩性胃炎的疗效,为合理用药提供一定借鉴。方法本研究采用对照分析法,选取慢性萎缩性胃炎伴Hp感染的老年患者80例为研究对象,并采用随机摸取号码的方式将其分成对照组和观察组,每组40例。两组均接受基础支持治疗,对照组在此基础上采用艾司奥美拉唑肠溶胶囊,观察组则采用莫沙必利联合艾司奥美拉唑肠溶胶囊。治疗4周后,分析两组患者的治疗效果以及治疗前后血清炎症因子指标(TNF-α、IL-8和IL-6)。结果观察组的临床疗效优于对照组,差异有统计学意义(P<0.05)。与治疗前比,两组治疗4周时血清炎症因子指标(TNF-α、IL-8和IL-6)下降(P<0.05);与对照组比,观察组治疗4周时血清炎症因子指标(TNF-α、IL-8和IL-6)较低(P<0.05)。结论莫沙必利与艾司奥美拉唑肠溶胶囊的联合应用,能够有效提升老年慢性萎缩性胃炎的治疗效果,并显著降低炎症因子水平,该联合治疗方案在临床实践中具有较高的推广价值。
Objective To observe the effect of Moxapride combined with esomeprazole enteric-coated capsule on chronic atrophic gastritis of the elderly,and provide some reference for rational drug use.Methods 80 elderly patients with chronic atrophic gastritis accompanied by Hp infection were selected as subjects,and divided into two groups with randomly fetching numbers based on data collection.Two groups were treated with basic support treatment,the control group(n=40)with esomeprazole enteric-coated capsule;and the observation group(n=40)with moxapride combined with esomeprazole enteric-coated capsule.Two groups of patients were treated with course of 4 weeks.Clinical effect was evaluated with software.Serum inflammatory cytokines(TNF-α,IL-8 and IL-6)were measured by venous blood before and after treatment.Results Clinical effect of the observation group was better than the control group,with statistical significance(P<0.05).Compared with before treatment,serum inflammatory factor indexes(TNF-α,IL-8 and IL-6)decreased in 2 groups after 4 weeks of treatment(P<0.05).Compared with the control group,the serum inflammatory factor indexes(TNF-α,IL-8 and IL-6)in the observation group were lower after 4 weeks of treatment(P<0.05).Conclusion Moxapride combined with esomeprazole enteric-coated capsule can improve the effect of chronic atrophic gastritis of the elderly and reduce inflammatory factors,which is worthy of clinical promotion.
作者
王丹丹
WANG Dandan(Department of Gastroenterology,Pingliang City the Second People’s Hospital,Pingliang,Gansu,744000)
出处
《智慧健康》
2024年第29期40-42,49,共4页
Smart Healthcare
